Price (delayed)
$22.23
Market cap
$1.46B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.92
Enterprise value
$1.39B
Chinook Therapeutics, Inc. is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined
There are no recent dividends present for KDNY.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.